Abstract
Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Keywords: Lung, nitrofurantoin, toxicity
Current Drug Safety
Title: Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Volume: 5 Issue: 2
Author(s): Emilia Hardak, Gidon Berger, Norberto Krivoy, Anna Solomonov and Mordechai Yigla
Affiliation:
Keywords: Lung, nitrofurantoin, toxicity
Abstract: Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Export Options
About this article
Cite this article as:
Hardak Emilia, Berger Gidon, Krivoy Norberto, Solomonov Anna and Yigla Mordechai, Nitrofurantoin Pulmonary Toxicity: Neglected Threat, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936169
DOI https://dx.doi.org/10.2174/157488610790936169 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sarcoidosis and Sarcoid Reactions in Endometrial Cancer Cases Masquerading
Advanced Stage Malignancy
Current Women`s Health Reviews The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Nitrofurantoin Pulmonary Toxicity: A Brief Review
Current Respiratory Medicine Reviews Novel PET Tracers in the Management of Cardiac Sarcoidosis
Current Radiopharmaceuticals The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Age-related Vascular Differences among Patients Suffering from Multiple Sclerosis
Current Neurovascular Research HCV and Autoimmunity in Rheumatic Diseases
Current Rheumatology Reviews Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Vasculitis: Decade in Review
Current Rheumatology Reviews Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design